CareDx, Inc.
Mar 8, 2016

CareDx Receives Positive Coverage Decision for AlloMap® From TRICARE® Covering Over 9 Million Lives of U.S. Military Members and Their Families

BRISBANE, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the receipt of positive coverage from TRICARE® National Insurance for AlloMap®.    

As a part of the military health system, TRICARE is the health care program for active and returned service members and their dependents.  TRICARE has over 9 million lives covered in their programs.   This positive coverage decision applies to all TRICARE regions and offers retroactive coverage of AlloMap from February 2015 onwards. 

"The positive coverage decision for AlloMap by TRICARE is deserved by individuals in the military and their beneficiaries who are heart transplant patients," said Jim Yee, MD PhD, Chief Medical Officer.   "Our military service population who are covered by TRICARE will now have the same access that is available through non-military health plans.  We hope that this decision will ensure that patients covered by TRICARE will no longer have barriers to access AlloMap testing services." 

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. For more information, please visit: www.CareDx.com

Media Contacts - CareDx

Molly Martell, Senior Director, Marketing

T: +1 415-728-6307

E: mmartell@caredx.com



Media Contacts - Investor

Jamar Ismail, Vice President

Westwicke Partners, LLC

T:  +1 650-996-8777

E:  jamar.ismail@westwicke.com







Primary Logo

Source: CareDx, Inc.

News Provided by Acquire Media